financetom
Business
financetom
/
Business
/
CyberArk Software Q2: Revenue Jumps 28% With Strong Subscription Growth, 2024 Outlook Raised
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CyberArk Software Q2: Revenue Jumps 28% With Strong Subscription Growth, 2024 Outlook Raised
Aug 8, 2024 8:39 AM

CyberArk Software Ltd ( CYBR ) reported fiscal second-quarter 2024 revenue growth of 28% year-on-year to $224.7 million, beating the analyst consensus estimate of $219.1 million. 

The information security company posted an adjusted EPS of 54 cents, which beat the analyst consensus estimate of 40 cents. The stock price gained after the print.

Segments: Revenues from Subscriptions expanded 49% Y/Y to $158.4 million. Maintenance and professional services were $62.7 million vs. $64.6 million Y/Y.

Key Performance Indicators: Annual Recurring Revenue (ARR) increased 33% Y/Y to $868 million. The subscription portion of ARR was $677 million, implying a 50% Y/Y growth. 

The Maintenance portion of ARR was $191 million, compared to $201 million Y/Y. Recurring revenue grew 32% Y/Y to $208.0 million. 

CyberArk held $1.4 billion in cash and equivalents as of June 30, 2024.

CEO Matt Cohen said, “With the explosion of new identities, new environments, and new attack methods, a new paradigm is needed to protect every identity – human or machine – with the right level of privilege controls. Customers are consolidating on our platform, driving land and expand, as evidenced by the 245 new logos we signed and our net new Subscription ARR of $56 million.” 

Outlook: CyberArk expects a fiscal third-quarter revenue of $230.0 million to $236.0 million, versus the consensus of $219.1 million.

It projected an adjusted EPS of 38 cents to 49 cents, versus the consensus of 40 cents.

CyberArk projected fiscal 2024 revenue of $932.0 million–$942.0 million (prior $928.0 million–$938.0 million) versus the consensus of $935.1 million. 

CyberArk expects an adjusted EPS outlook of $2.17–$2.36 (prior $1.88–$2.07) versus the consensus of $2.03.

ARR as of December 31, 2024, will likely range between  $985 million–$995 million (prior $975 million–$990 million), up by 27%–29%.

CyberArk Software ( CYBR ) stock gained 82% in the last 12 months.

Price Action: CYBR stock traded higher by 7.5% at $261.54 at last check Thursday.

Read Next:

Fed Rate Cuts Could Avert Recession, Say 75% In Benzinga Poll: Majority See Market Dip As Temporary

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump
Apr 26, 2024
10:56 AM EDT, 04/26/2024 (MT Newswires) -- Biodexa Pharmaceuticals ( BDRX ) said Friday it has signed a deal with Emtora Biosciences for the exclusive, global rights for eRapa, a phase 3-ready drug to treat familial adenomatous polyposis, an inherited condition that affects the gastrointestinal tract. Shares of the company rose more than 81% in recent Friday trading. The license...
Update: AppFolio Swings to Q1 Adjusted Earnings, Revenue Rises; Lifts 2024 Revenue Guidance; Shares Climb
Update: AppFolio Swings to Q1 Adjusted Earnings, Revenue Rises; Lifts 2024 Revenue Guidance; Shares Climb
Apr 26, 2024
11:01 AM EDT, 04/26/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph) AppFolio ( APPF ) shares were up more than 16% in recent trading on Friday, a day after the company posted stronger-than-expected Q1 earnings and raised 2024 revenue guidance. The company reported late Thursday it swung to Q1 adjusted earnings of $1.05...
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe
Apr 26, 2024
11:00 AM EDT, 04/26/2024 (MT Newswires) -- Amgen ( AMGN ) said Friday it will submit a marketing authorization application to the European Medicines Agency for the teprotumumab medicine to treat moderate to severe thyroid eye disease in adults. Teprotumumab is approved for thyroid eye disease treatment in the US, Brazil and Saudi Arabia under the brand name Tepezza, the...
Update: ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17%
Update: ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17%
Apr 26, 2024
11:01 AM EDT, 04/26/2024 (MT Newswires) -- (Updates to include recent stock movement in the headline and first paragraph.) ResMed ( RMD ) shares rose by more than 17% in recent Friday trading after the company reported fiscal Q3 non-GAAP earnings of $2.13 per diluted share, up from $1.68 a year earlier. Analysts surveyed by Capital IQ expected $1.91. Revenue...
Copyright 2023-2026 - www.financetom.com All Rights Reserved